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Cerebral malaria is associated with decreased production of nitric oxide and decreased levels of its precur­
sor, f.-arginine. Abnormal amino acid metabolism may thus be an important factor in malaria pathogenesis.
We sought to determine if other amino acid abnormalities are associated with disease severity in falciparum 
malaria. Subjects were enrolled in Dar es Salaam, Tanzania (children) (n = 126), and Papua, Indonesia 
(adults) (n = 156), in two separate studies. Plasma samples were collected from subjects with WHO-defined 
cerebral malaria (children), all forms of severe malaria (adults), and uncomplicated malaria (children and 
adults). Healthy children and adults without fever or illness served as controls. Plasma amino acids were 
measured using reverse-phase high-performance liquid chromatography with fluorescence detection. Several 
plasma amino acids were significantly lower in the clinical malaria groups than in healthy controls. Despite the 
differences, phenylalanine was the only amino acid with mean levels outside the normal range (40 to 84 |jiM )  
and was markedly elevated in children with cerebral malaria (median [95% confidence interval], 163 [134 to 
193] |jiM ; P < 0.0001) and adults with all forms of severe malaria (median [95% confidence interval], 129 [111 
to 155] |jiM ; P < 0.0001). In adults who survived severe malaria, phenylalanine levels returned to normal, with 
clinical improvement (P = 0.0002). Maintenance of plasma phenylalanine homeostasis is disrupted in severe 
malaria, leading to significant hyperphenylalaninemia. This is likely a result of an acquired abnormality in the 
function of the liver enzyme phenylalanine hydroxylase. Determination of the mechanism of this abnormality 
may contribute to the understanding of neurological complications in malaria.
The coma of ccrcbral malaria (CM) is frequently accompa­
nied by seizures and abnormalities of muscle tone and posture 
(23). The mechanisms of these neurological complications arc 
unclear; however, ccrcbral ischemia is unlikely to be the sole 
explanation, as survivors arc usually neurologically intact (17). 
Altered amino acid metabolism in response to malaria infec­
tion may contribute to disease severity. Circulating amino acids 
serve primarily as substrates for protein synthesis, metabolic 
energy (oxidation through the carboxylic acid cycle), or glu- 
coneogenesis and ketogcnesis. Importantly, certain amino ac­
ids arc also substrates for neurochemical mediators, which can 
be increased by inflammatory stimuli. For example, gamma 
interferon increases metabolism of tryptophan through the 
kynurenine pathway, resulting in the production of the excita­
tory mediators quinolinic acid, kynurenic acid, and picolinic 
acid. These have been investigated as possible contributors to 
the neurologic dysfunction of CM (15).
We have previously shown that plasma levels of the nitric
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oxide (NO) precursor i-arginine were significantly reduced in 
African children with CM relative to levels in healthy controls 
(HC) and those with uncomplicated malaria (UM) (14). In 
addition, case fatality rates from CM were independently as­
sociated with the degree of hypoargininemia. These results 
paralleled previous work demonstrating similarly reduced sys­
temic levels of NO metabolites and NO synthase expression in 
blood mononuclear cells from children with CM relative to 
those of patients with UM and controls (I). In extending our 
amino acid analysis from those previous studies, we discovered 
abnormalities in plasma phenylalanine levels in children with 
malaria. Additionally, we measured phenylalanine levels in 
plasma collected from Indonesian adults with severe malaria 
(SM) and UM. Here, we describe our findings and discuss how 
they may relate to the neurological complications of CM.
MATERIALS AND METHODS
Subjects. Plasma samples analyzed in this study were collected from a previous 
study of NO and malaria involving children aged between 6 months and 7 years 
from Dar es Salaam (1), Tanzania. Since publishing plasma arginine levels in 
Tanzanian children with malaria (14), we have located additional stored plasma 
samples (19 IIC, 19 UM, and 13 CM samples) from the original cohort of 
children (1). These samples were included for analysis in the present study.
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TABLE 1. Characteristics of subjects in Tanzanian study groups 
upon enrollment"
Variable HC (n = 38) UM (n = 36) CM (n = 5 1 )
Age (yr) 4.6 ±  2.3 3.4 ±  2.0 3.6 ±  1.9
% M ale 63 56 53
W t (kg) 15.0 ±  4.8 12.5 ±  3.8 12.6 ±  3.5
Tim e since last 12.6 ±  1.1 7.1 ±  10 15.8 ±  13.6
m eal (h)
W hite b lood cell 8.1 ±  1.9 11.1 ±  5.5 17.0 ±  10.6
count (lO ’/ixl)
H em oglobin level 11.0 ±  1.6 7.4 ±  2.3 6.3 ±  2.2
(g/liter)
Plasm a creatin ine 36.3 ±  10.4 37.6 ±  8.9 61.7 ±  35
level (ixmol/liter)
G eom etric  m ean 328;> 55,872 35,789
parasitem ia
(trophozoites/|x l)
Data are presented as means ±  standard deviations, except for parasitemia. 
b Refers to those with asymptomatic parasitemia (n =  5).
Reanalysis of arginine levels including the recently located samples does not 
change any interpretation made in the previous publication (14). However, for 
the total number of samples now available, the mean arginine level for HC 
children was significantly less (122 versus 103 |xM), as was the mean arginine 
level for subjects UM (70 versus 56 |xM). The mean arginine levels for children 
with CM (45.4 versus 45 |xM) and the statistical association between plasma 
arginine concentration and case fatality remain unchanged. Amino acids were 
also measured in plasma collected from Indonesian adults, aged 14 to 60 years, 
in Papua, Indonesia. Study subjects had been enrolled in the following groups: (i) 
CM (children) and SM (adults), defined using modified WHO criteria (20); (ii) 
UM (children and adults) (1); and (iii) HC (adults and children) (1, 2). Plasma 
samples were collected upon enrollment in the study and were stored at —80°C. 
Some adults had received quinine prior to enrollment, and the duration of 
quinine therapy prior to sample collection was recorded. A  second plasma 
sample was collected from adult SM survivors 3 days after enrollment but was 
unavailable for children and adults who died with SM (all deaths occurred within 
the first 3 days). All patients diagnosed with CM or SM were managed according 
to national protocols and treated with intravenous quinine. Institutional review 
board approval was given for the study, and informed consent was obtained from 
participants or their guardians.
Analytical methods. Samples were prepared as described previously (14) and 
derivatized with AccQFluor Reagent (Waters Corp.) according to the manufac­
turer’s recommendations. A  standard curve was prepared in a similar fashion. 
Alpha-aminobutyric acid was used as an internal control. Ten microliters of 
derivatized sample was used to quantify amino acid levels using reverse-phase 
high-performance liquid chromatography (HPLC) with gradient conditions and 
fluorescence detection. Three solutions were used to generate the gradient at a 
flow rate of 1 ml/minute: solution A  (AccQFluor Eluent A  [Waters Corp.]), 
solution B (100% HPLC-grade acetonitrile), and solution C (double-deionized 
water). The gradient was generated according to the manufacturer’s recommen­
dations (Waters Corp.). Intra-assay variability was 0.65%, and interassay vari­
ability was 1.4%. With this method, we were able to quantify levels of basic amino 
acids (arginine, ornithine, and lysine), aromatic amino acids (phenylalanine and 
tyrosine), and neutral amino acids (histidine, leucine, and isoleucine). There was 
no difference in the phenylalanine levels of HC adults and those of HC children; 
therefore, the normal range for plasma phenylalanine was generated by combin­
ing all HC data from Tanzanian and Indonesian groups and is based on the 
mean ±  2 standard deviations. For phenylalanine, this range was 40 to 84 |xM. 
The normal ranges generated by our method conformed closely to those estab­
lished by the Biochemical Genetics Section, ARUP Laboratories, University of 
Utah, where analysis was performed using ion-exchange chromatography with 
detection using spectrophotometry after a reaction with ninhydrin. The small 
volumes of plasma available from the majority of our subjects precluded amino 
acid analysis by this method. Plasma samples from healthy Caucasians and study 
subjects with sufficient volume were analyzed both by our method and at the 
Biochemical Genetics Section, ARUP Laboratories, University of Utah. Reli­
ability, denoted R, between the two amino acid assays was calculated using the 
intraclass correlation coefficient. In the calculation, the assay method was con­
sidered a fixed effect, since inference applies only to these two specific methods
TABLE 2. Characteristics of adult subjects in Indonesian study 
groups upon enrollment"
Variable* I1C (n = 43) UM (n = 43) SM (n = 70)
Age (yr) 27.4 ± 1 0 .1 29.3 ±  9.3 26.7 ±  9.4
W t (kg) 56.1 ±  7.2 56.6 ±  8.7 54.4 ±  8.1
% M ale 50 64 82
W hite cell count 7.6 ±  2.8 7.2 ±  7.7 9.0 ±  4.1
(10‘Vliter)
H b (g/dl) 12.9 ±  3.0 12.8 ±  1.9 9.6 ±  3.0
Plasm a creatin ine level 77.2 ±  13.0 89.8 ± 1 6 .1 270.4 ±  266.2
(ixmol/liter)
T im e from  last m eal (h) 12.0 ±  0.3 11.3 ±  5.7 16.5 ±  14.8
C hloroqu ine use p rio r 23 (53) 28 (40)
to study enro llm ent
[no. o f pa tien ts (% )]
D uration  o f quinine 0 3.1 ±  5.3 9.1 ± 1 1 .6
trea tm en t p rio r to
enro llm ent (h)
A L T  level (U /liter) 15.9 ±  6.3 29.4 ±  27.2 46 ±  37.7
I IC O , level (m m ol/liter) 28.8 ±  1.7 25.2 ±  2.2 25.4 ±  5.1
G eom etric  m ean 149' 4,136 10,605
parasitem ia
(trophozoites/|x l)
All values represent means ±  standard deviations, except for parasitemia. 
b Hb, hemoglobin; ALT, alanine aminotransferase.
Applies only to those with asymptomatic parasitemia.
(8). A  generally accepted rule of thumb for interpreting the reliability coefficient 
is as follows: R <  0.4 represents poor reliability, 0.4 <  R <  0.75 represents fair 
to good reliability, and R >  0.75 represents excellent reliability. The reliability 
coefficients between the two amino acid assays were as follows: phenylalanine, R —
0.99; tyrosine, R — 0.84; arginine, R — 0.77; ornithine, R — 0.81; lysine, R — 0.71; 
histidine, R — 0.55; leucine, R — 0.70; and isoleucine, R — 0.66, all of which are 
acceptable levels of reliability. Based on these results, we were confident in using 
HPLC for amino acid analysis.
Statistical methods. Fisher’s exact test was used to compare proportions. 
Continuous variables were compared using an independent-groups t test if nor­
mality assumptions were met; otherwise, groups were compared using the Mann- 
Whitney U test. Longitudinal data were analyzed using a paired t test. Multiple 
linear regression was used to control for confounding variables. Variables with 
extreme skewness or kurtosis were log transformed to meet the normality as­
sumption for use in these linear regression models. All statistical analyses were 
performed using Stata 8.0 software. P values of <0.05 were considered to be 
statistically significant.
RESULTS
Of the 191 children in the original Tanzanian study (1), 126 
(38/50 [76%] HC, 36/55 [65%] with UM, and 52/86 [60%] with 
CM) had a sufficient amount of plasma available for amino 
acid analysis. Of the 52 children with CM in this study, 20 died 
and 32 survived (38% case fatality). The case fatality in the 
original study was 30%' (26/86) ( I). Patient characteristics were 
published previously (I, 14) and arc listed in Table 1 for our 
subset. Fourteen children with CM had concomitant severe 
malarial anemia, but none had acute renal failure. In a sepa­
rate study of Indonesian adults with SM, plasma samples from 
156 adults (43 HC, 43 UM, and 70 SM samples) were available 
for sampling. Adult patient characteristics at enrollment arc 
listed in Table 2. In the SM group, 57 survived and 13 died. 
Fifty-eight percent of adults presenting with SM had CM, 
34.3%' had renal failure, and 2.7% had severe anemia. Seven 
(9.6%) patients with SM had both renal failure and CM, five 
(71 %) of whom died. No deaths occurred in either adult or 
childhood UM groups.
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T A B L E  3. Plasm a am ino acid levels in T anzan ian  children1'
Amino acid
Mean amino acid level (jxM) ± SD
Normal range*’ IIC (n = 38) UM (n = 36) CM (n = 52)
Phenvlalanine 30-80 61 ±  13 118 ±  52" 177 ±  81"'J
Tyrosine 30-120 50 ±  10 53 ±  13 85 ±  47"-J
Phe/Tyr ratio 1.3 ±  0.32 2.4 ±  1.2‘' 2.2 ±  0.9"
A rginine 40-160 100 ±  32 56 ±  22" 45 ±  15"
O rn ith ine 20-135 64 ±  24 37 ±  15" 34 ±  12"
Lysine 80-250 151 ±  31 94 ±  28" 108 ±  47"
H istidine 50-130 80 ±  25 61 ±  18" 65 ±  20"
Leucine 60-230 116 ±  36 118 ± 5 1 139 ±  41",J
Isoleucine 30-130 63 ±  20 71 ±  38 54 ±  18
“ Groups compared using Wilcoxon-Mann-Whitney losl with significance de­
lined as a P value of <0.0)3, given multiple groups.
b Normal range as established by (he Biochemical Genetics Section, ARUP 
Laboratories, University of Utah.
" Significantly different from TIC (P <  0.013). 
d CM significantly dili'eren! I'rom UM (P <  0.013).
In addition to dccrcascd arginine levels relative to controls 
reported previously (14), in children, there were statistically 
significant decreases in ornithine, lysine, and histidine levels in 
all clinical malaria groups compared to levels in HC (Table 3).
Despite significant differences, the mean plasma levels of these 
amino acids were within the normal ranges established for 
screening for inherited metabolic diseases in children. By con­
trast, phenylalanine was the only elevated amino acid in the 
malaria groups, with the mean greater than the upper limit of 
the normal range (Fig. 1 and Table 3). The proportion of 
children with abnormal phenylalanine levels was significantly 
greater in the CM group (49/52 [94%]) than in the UM group 
(27/36 [75%]) (P = 0.013). Likewise, the proportions in adults 
with hyperphenylalaninemia was higher in the SM group 
(53/70 [76%]) than in the UM group (19/43 [44%]) (P =
0.001). In contrast, only 2 of 38 HC children and 0/43 HC 
adults had elevated phenylalanine levels. The degree of hyper­
phenylalaninemia correlated with disease severity, with levels 
in CM and SM groups significantly greater than those in the 
respective HC and UM groups (Fig. la  and b). This association 
remained after controlling for age, weight, duration of fasting, 
use of chloroquine prior to admission, duration of quinine use 
prior to sample collection, biochemical hepatitis, and renal 
function using linear regression. There was no association be­
tween phenylalanine levels and CM case fatality in children;
FIG . 1. Plasm a phenylalanine concen trations in severe m alaria, (a) D ay 0 levels in T anzanian  children  w ith CM . (b) D ay 0 levels in Indonesian  
adults w ith SM. (c) Day 0 levels in Indonesian  adults by outcom e, death  (m edian  [95% confidence interval], 275 [163 to 399] |xM) versus survival 
(m edian  [95% confidence interval], 118 [90 to 140] |xM). (d) L ongitudinal data  for Indonesian  adults on  day 0 (m edian  [95% confidence interval], 
116 [86 to 133] |xM) and day 3 (m edian  [95% confidence interval], 76 [70 to 90] |xM) o f  the  study. Box plot, m edian and interquartile range; whiskers, 
maximum/minimum range; dotted lines, phenylalanine m eans ±  2 standard deviations (norm al range) based on 80 I IC  samples. Differences between 
m eans were com pared using a W ilcoxon-M ann-W hitney test. Longitudinal data were com pared using a paired two-tailed t test.
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however, levels were higher in SM case fatalities than in sur­
vivors (Fig. Ic). Phenylalanine levels did not differ between 
adults with CM and those with other forms of SM or between 
adults with and without renal failure. Phenylalanine levels were 
significantly decreased by day 3 of treatment in SM survivors 
but did not completely normalize (Fig. Id). Hyperphenylala- 
ninemia was not correlated with coma score in children with 
CM or in adults with SM.
Tyrosine, the single, immediate product of phenylalanine 
metabolism by hepatic phenylalanine hydroxylase, was in­
creased in CM (Table 3) and SM (mean ± SD.'SI ± 46 |xM) 
groups only. The significance of this finding is unclear, as 
tyrosine levels in CM and SM groups were within the normal 
range. Moreover, provoked hyperphenylalaninemia in healthy 
adults leads to a mild elevation of plasma tyrosine levels (19). 
To better define the mechanism of hyperphenylalaninemia, we 
calculated the phenylalanine/tyrosine ratio, a sensitive measure 
of phenylalanine hydroxylase activity. This ratio has been used 
for the detection of heterozygous carriers of phenylketonuria 
mutant genes (9), as impairment of phenylalanine hydroxylase 
leads to ratios above normal (0.8 to 1.2) (3). The phenylala­
nine/tyrosine ratio was increased in all groups with clinical 
malaria but was not different between mild and severe disease 
(Table 3). This was due in part to increases in plasma tyrosine 
levels in the CM and SM groups.
DISCUSSION
The causes and sequelae of chronic hyperphenylalaninemia 
have been well characterized in children with inborn errors of 
phenylalanine metabolism. However, less is known about the 
physiologic consequences of acute perturbations in phenylala­
nine metabolism, especially in infectious diseases. Hyperphe­
nylalaninemia and an elevated phenylalanine/tyrosine ratio in 
children with falciparum malaria have been observed in one 
previous study in which four children with CM had elevated 
phenylalanine concentrations (7) similar to the levels we mea­
sured. Inhibition of phenylalanine metabolism has also been 
reported in sepsis of various etiologies (4, 6, 21) but to a lesser 
degree than that observed in CM. Despite these observations, 
the mechanism by which hyperphenylalaninemia develops in 
acute infections has not been established. Release of phenyl­
alanine into the circulation from skeletal muscle catabolism 
may be an important factor. Under normal circumstances, ex­
cess phenylalanine (e.g., phenylalanine loading test) leads to 
substrate-level regulation of hepatic phenylalanine hydroxylase 
activity with consequent lowering of plasma phenylalanine lev­
els within a narrow range (40 to 84 jjiM). This enzyme converts 
phenylalanine to tyrosine in an oxygen- and pterin-dependent 
reaction (Fig. 2). The elevated phenylalanine/tyrosine ratio in 
malaria suggests that hyperphenylalaninemia results from im­
paired phenylalanine hydroxylase activity in the liver.
Hyperphenylalaninemia in malaria may have important 
physiologic consequences. Two examples come from inborn 
errors affecting aromatic amino acid metabolism (e.g., phe­
nylketonuria and dopamine-responsive dystonia [DRD]) that 
lead to neurological abnormalities. These genetic diseases im­
pair phenylalanine hydroxylase activity by different mecha­
nisms, and both cause chronic neurological disease in children. 
Phenylketonuria arises from inherited mutations in the phe-
F IO . 2. R ela tionsh ip  o f  te ti'ahydrob iop terin -dependent arom atic 
am ino acid m etabolism  to biogenic am ine neuro transm itte i' synthesis. 
T he plasm a concen tra tion  o f  L-phenylalanine is regulated  by changes 
in the activity o f  hepatocyte  phenylalanine hydroxylase (P A II). P h e ­
nylalanine hydroxylase activity depends in part on  hepatocyte synthesis 
o f its obligatory cofactor, te trahydrob iop terin  (B II4). Tyrosine, the 
phenylalanine hydroxylase reaction  p roduct, en te rs  the  blood and is 
taken up by neu rons for fu rther synthesis to l-D O P A  (3,4-dihydroxy- 
phenylalanine) by tyrosine hydroxylase (T il) ,  ano ther B II4-dependen t 
enzym e. l-D O P A  serves as the  p recu rso r for synthesis o f  several b io­
genic am ine n eu ro transm itte rs (dopam ine, n o rep inephrine , and ep i­
n ephrine), beginning w ith the  enzym e L-amino acid decarboxylase 
(A D C C ).
nylalanine hydroxylase gene that lead to persistent elevations 
in plasma phenylalanine levels up to 50 times greater than 
normal. High concentrations of plasma phenylalanine lead to 
phenylalanine accumulation in the brain, which is neurotoxic 
(12). In contrast, DRD is caused by a tetrahydrobiopterin 
deficiency from loss-of-function mutations in the GTP cyclo- 
hydrolase gene, the rate-limiting enzyme for tetrahydrobio­
pterin biosynthesis. Tetrahydrobiopterin is a required cofactor 
not only for phenylalanine hydroxylase but also for other en­
zymes (i.e., neuronal NO synthase, tryptophan hydroxylase, 
tyrosine hydroxylase, and dopamine p-hydroxylase) essential 
for brain neurotransmitter biosynthesis (16) (Fig. 2). DRD 
manifests with mild hyperphenylalaninemia, decreased mono­
amine neurotransmitter metabolite levels in the spinal fluid, 
and neurological dysfunction independent of plasma phenylal­
anine levels (18).
An underlying genetic phenylalanine hydroxylase abnormal­
ity as a cause of hyperphenylalaninemia in malaria is unlikely, 
since we would not have expected a rapid correction of plasma 
phenylalanine levels and the phenylalanine/tyrosine ratio (data 
not shown) upon clinical improvement with conventional treat­
ment. Moreover, the degree of hyperphenylalaninemia that we 
observed in malaria is not consistent with the extreme eleva­
tions seen in phenylketonuria. Given the phenotypic similari­
ties between children with DRD and children with CM (e.g., 
somnolence, recurrent seizures, motor dystonia, abnormal pos­
turing, and autonomic instability) (18), we favor an acquired 
tetrahydrobiopterin deficiency as a more plausible explanation 
for hyperphenylalaninemia in malaria.
There is minimal passage of tetrahydrobiopterin across the 
blood-brain barrier (13). Thus, neurotransmitter production 
requires local de novo synthesis of this cofactor. Brain tetra-
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hydrobiopterin deficiency in CM, but not UM, is a possible 
explanation for the absence of neurological symptoms in indi­
viduals with UM and hyperphenylalaninemia. Tetrahydrobio­
pterin levels have been measured in the spinal fluid of African 
children with CM in two separate studies, revealing conflicting 
results. One study of Zambian children with CM revealed 
that low total biopterin (biopterin, dihydrobiopterin, and tetra­
hydrobiopterin) in cerebral spinal fluid correlated with deep 
coma (22). Another study in coastal Kenya reported elevated 
tetrahydrobiopterin levels in subjects with CM that were more 
than 10 times higher than those measured in Zambian children 
(5). The discrepant results highlight the difficulties in measur­
ing biopterin metabolites in biologic fluids (1 0 ), especially in 
clinical studies of malaria in developing countries (11). Hence, 
whether systemic and/or central nervous system tetrahydro­
biopterin deficiency is present in malaria remains an open 
question.
In conclusion, we have shown that children with CM and 
adults with all forms of SM have disordered phenylalanine 
metabolism, which may result from impaired hepatic phenyl­
alanine hydroxylase activity. Whether hyperphenylalaninemia 
is associated with brain neurotransmitter and pterin abnormal­
ities in CM has therapeutic implications (such as adjunctive 
tetrahydrobiopterin replacement therapy) and warrants fur­
ther investigation.
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